Clinical trials: SBRT
Lymph Node Cancer Metastatic
High Dose SBRT for Abdominal-Pelvic Lymph Nodal Lesions in Oligometastatic Patients
This is a prospective, multicentric, phase II and feasibility study aimed to address early and late side effects of hypofractionated ablative radiotherapy for oligometastatic patients with lymph node metastases for…
- Trial name
- NCT02570399
- Testing
- Oligometastatic patients with abdominal-pelvic lymph nodes
- Where
- Italy
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
Bone Metastases, Radiotherapy Side Effect
A Prospective Randomized Trial of High Dose Versus Standard Dose Stereotactic Radiotherapy for Pain Control in Patients With Bone Metastases
In the present study, we will prospectively evaluate the pain response and treatment failure rate to determine the most favorable radiation dose in single fraction stereotactic radiotherapy using the modern highly conformal…
- Trial name
- NCT04063254
- Testing
- Stereotactic Radiotherapy
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
HepatoCellular Carcinoma
Comparison of SBRTand Repeat TACE for HCC
Comparison of Stereotactic Body Radiation Therapy (SBRT) and repeated transarterial chemoembolization (TACE) for Hepatocellular Carcinoma (HCC)as a Local Salvage Treatment after first incomplete TACE
- Trial name
- STH (NCT03326375)
- Testing
- SBRT
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gangneung Asan Hospital
Metastasis From Malignant Tumor of Soft Tissues
SBRT Treatment for Lung Metastasis From Soft Tissue Sarcoma
In this study the investigators treat PM oligometastatic patients with SBRT. Our objective is to evaluate rate of local control of treated lesions in patients treated with Intensity Modulated Radiation Therapy (IMRT) using…
- Trial name
- NCT02561559
- Testing
- Lung metastasis from soft-tissue sarcoma
- Where
- Italy
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
Glioblastoma
Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2)
This is a prospective multicenter study of hypofractionated radiotherapy for the radiation treatment (RT) of solid tumors and in particular for Glioblastoma (in Aim 2).
- Trial name
- NCT06551909
- Testing
- Neoaddjuvant Stereotactic Radiotherapy with Simultaneous Integrated Boost
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Esophageal Squamous Cell Carcinoma, Oligometastatic Disease
Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC
The goal of this phase II clinical trial is to explore the efficacy and safety of anti-PD1 combined with stereotactic body radiation therapy (SBRT) for patients with oligometastatic esophageal squamous cell carcinoma.
- Trial name
- NCT05626569
- Testing
- PD-1 combined with SBRT
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy (SBRT) in Hepatocellular Carinoma
Hypothesis: Patients with hepatocellular carcinoma (HCC) have few options if they fail or are unable to undertake surgery, transarterial chemoembolization (TACE) and/or chemotherapy.
- Trial name
- TACERT (NCT03079778)
- Testing
- transarterial chemoembolization, TACE plus RT
- Volunteers
- healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Nasopharyngeal Cancinoma (NPC), SBRT
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
This study is a single-arm, open-label, prospective, and exploratory investigation aimed at examining the short-term efficacy, specifically the objective response rate (ORR), of SBRT combined with Nimotuzumab followed by…
- Conditions
- Nasopharyngeal Cancinoma (NPC), SBRT, Immunotherapy
- Trial name
- NCT06676722
- Testing
- SBRT combined with Nimotuzumab followed by Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xiamen University